Literature DB >> 19912125

Acute respiratory distress syndrome: insights gained from clinical and translational research.

Marija Kojicic1, Emir Festic, Ognjen Gajic.   

Abstract

Acute lung injury and its more severe form acute respiratory distress syndrome (ARDS) are characterized by diffuse impairment of alveolocapillary membrane in the settings of different predisposing conditions such as sepsis, trauma and shock. Many intrahospital exposures, including aspiration, delayed resuscitation, high tidal volume mechanical ventilation and non critical use of transfusions may contribute or worsen ARDS. Therapy is targeted to treatment of predisposing condition, life supportive measures and prevention of nosocomial complications. Rigorous adherence to lung-protective mechanical ventilation is critical to prevent ventilator induced lung injury and decrease mortality. Although survival of ARDS patients has improved in the last decades ARDS mortality rates are still high and survivors encounter significant physical and psychological impairments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19912125     DOI: 10.17305/bjbms.2009.2764

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  3 in total

1.  Multifractal analysis on age-based discrimination in X-ray images for sensing the severity of COVID-19 disease.

Authors:  Shaobo He; C Thangaraj; D Easwaramoorthy; G Muhiuddin
Journal:  Eur Phys J Spec Top       Date:  2022-06-08       Impact factor: 2.891

2.  Multifractal based image processing for estimating the complexity of COVID-19 dynamics.

Authors:  Qiusheng Rong; C Thangaraj; D Easwaramoorthy; Shaobo He
Journal:  Eur Phys J Spec Top       Date:  2021-11-18       Impact factor: 2.707

3.  Generalized fractal dimensions based comparison analysis of edge detection methods in CT images for estimating the infection of COVID-19 disease.

Authors:  C Thangaraj; D Easwaramoorthy
Journal:  Eur Phys J Spec Top       Date:  2022-09-05       Impact factor: 2.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.